Key takeaway: Windlas Biotech Limited's investor presentation for Q1 FY27 reported an 18% year-over-year revenue growth, reaching ₹248 crore, marking the company's 14th consecutive quarter of record revenue. Management highlighted a strong performance in the Generic Formulations CDMO vertical, which saw a 29% revenue increase to ₹207 crore, driven by customer expansion and new product launches. The company completed a ₹47 crore buyback without promoter participation and declared a ₹13 crore dividend for FY26. Adjusted EBITDA grew 26% to ₹34 crore, while profit before tax and profit after tax increased by 27% and 37%, respectively. The presentation emphasized the company's focus on long-term value creation, operational excellence, and strategic partnerships, alongside plans for the commercialization of Plant-6 to enhance manufacturing capacity. Windlas Biotech aims to capitalize on growth opportunities across its business verticals, supported by a robust financial position and a talented workforce.

Key takeaway: During the Q4 and FY26 earnings conference call, management reported a 19% year-on-year revenue growth, reaching INR 904 crores for FY26, with Q4 revenue increasing 18% to INR 238 crores. The company highlighted its strong performance in the Generic Formulations CDMO vertical, which grew 20% year-on-year. Management noted the importance of maintaining capital efficiency, reporting a net liquidity position of INR 251 crores and a highest post-listing EPS of INR 31.60. The company also discussed its ongoing investments in quality systems and compliance infrastructure to meet regulatory standards. Management expressed optimism about future growth prospects, particularly in exports and injectables, while emphasizing a balanced approach to capital allocation and shareholder returns. The completion of a buyback program and a proposed dividend of INR 6.3 per share were also mentioned as reflections of the company's confidence in its future potential.

Key takeaway: Windlas Biotech Limited's investor presentation for Q4 and FY26 highlighted a 19% year-over-year revenue growth, reaching Rs. 904 Cr, with Q4 FY26 revenue at Rs. 238 Cr, an 18% increase. The Managing Director noted the company's focus on scalability and profitability, achieving its highest post-listing EPS of Rs. 31.60. The company reported strong cash flows of Rs. 105 Cr and maintained a net liquidity position of Rs. 251 Cr. The CEO emphasized the growth in the Generic Formulations CDMO vertical, which generated Rs. 664 Cr in FY26, and the Exports vertical, which grew by 40%. The presentation also detailed a proposed dividend of Rs. 13 Cr and a completed buyback of shares worth Rs. 47 Cr. Overall, the company demonstrated robust financial health and strategic investments in manufacturing capabilities.

Key takeaway: During the Q3 and 9 Months FY26 Earnings Conference Call, management highlighted that Windlas Biotech achieved record revenues with a year-on-year growth of 20% in Q3 FY26 and 19% for the first nine months. The company reported an earnings per share of INR24.02, reflecting a 12% increase year-on-year. Management noted that the Indian pharma market grew by 11.8% year-on-year in Q3 FY26, with Windlas Biotech's performance exceeding industry growth. The company is focused on expanding its manufacturing capabilities, with Plant 6 nearing mechanical completion. Management emphasized the importance of operational efficiencies and customer partnerships while expressing optimism about future growth opportunities across its verticals. The discussion also touched on the challenges in the Trade Generics segment and the impact of institutional orders on revenue fluctuations. Overall, management conveyed a commitment to creating long-term shareholder value through disciplined execution and strategic investments.

Key takeaway: Windlas Biotech Limited's investor presentation for the quarter and nine months ended December 31, 2025, reported a 19% year-over-year revenue growth for 9MFY26, reaching Rs 666 crore, and a 20% growth for Q3FY26, totaling Rs 233 crore. Management highlighted the company's strong performance across its business verticals, with the Generic Formulations CDMO segment growing by 20% in 9MFY26 and 23% in Q3FY26. The Trade Generics & Institutional vertical saw an 18% increase in 9MFY26, while exports grew by 29%. The presentation noted a focus on delivering affordable medicines and expanding customer partnerships. EBITDA for 9MFY26 was reported at Rs 89 crore, with a PAT of Rs 60 crore, reflecting a 28% increase year-over-year. The company emphasized its commitment to quality manufacturing and operational efficiency, aiming to leverage growth opportunities in the healthcare sector.